USPTO serial 79452995
OCHRE
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- MCDORMAN, ROGER THOMAS
- Law office
- TMEG LAW OFFICE 109
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with OCHRE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals; therapeutic agents; pharmaceuticals and therapeutics for the treatment of liver diseases, cirrhosis, hepatitis, metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver diseases, liver fibrosis, primary biliary cholangitis, fibrotic diseases and metabolic diseases; pharmaceuticals and therapeutics for the treatment of obesity, sarcopenia, metabolic disorders and muscular disorders; pharmaceuticals and therapeutics for the treatment of conditions affecting the liver; pharmaceuticals and therapeutics for use in the field of metabolics; RNA medicines; RNA synthesis inhibitors; culture media for cultivating human cells and tissue; cells and tissue for medical or clinical use. | ACTIVE | — |
| 035 | Data entry, collection, compilation, analysis and management services; information, advisory and consultancy services relating to all the aforesaid services. | ACTIVE | — |
| 042 | Software as a service (SaaS); software as a service (SaaS) for use in relation to pharmaceuticals, DNA analysis, genomic phenotyping, pharmaceutical research and drug discovery; application service provider featuring software for use in the visualisation of data; database design; technical data analysis; technical data analysis services in relation to pharmaceuticals, DNA analysis, genomic phenotyping, pharmaceutical research and drug discovery; drug screening for scientific research purposes; scientific and technical modelling services for use in relation to the research, design and development of pharmaceuticals, drugs and medicines; research and development of siRNA and mRNA drugs; pharmaceutical product evaluation; testing of pharmaceuticals; information, advisory and consultancy services relating to all the aforesaid services. | ACTIVE | — |
| 044 | Medical services in relation to cirrhosis, hepatitis, metabolic dysfunction-associated steatohepatitis (mash), alcoholic liver diseases, liver fibrosis, primary biliary cholangitis, fibrotic diseases, metabolic diseases, the treatment of obesity, sarcopenia, metabolic disorders, muscular disorders and the treatment of conditions affecting the liver; provision of medical information about genomic phenotyping and the treatment of conditions affecting the liver; provision of medical information and data for use in relation to the research, design and development of pharmaceuticals, drugs and medicines; information, advisory and consultancy services relating to all the aforesaid services. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 8, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 24, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 24, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 15, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 14, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 1, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 1, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 25, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |